ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine
Vrana, E. Timmins, H. Osborne, A. Cox, R. Wasan, H. Ma, Y. T. Arora, A. Faluyi, O. Gillmore, R. Corrie, P.
Vrana, E.
Timmins, H.
Osborne, A.
Cox, R.
Wasan, H.
Ma, Y. T.
Arora, A.
Faluyi, O.
Gillmore, R.
Corrie, P.
Abstract
Until recently, cisplatin/gemcitabine was standard of care for the first-line treatment of patients with advanced biliary tract cancer (BTC). The addition of durvalumab, an immune checkpoint inhibitor, to the combination of cisplatin/gemcitabine has demonstrated an overall survival (OS) benefit and is now a standard of care first-line treatment option. BTCs exhibit immunogenic features may develop through an accumulation of genetic and epigenetic alterations, and can be influenced by microbial exposure. Microbiota can influence inflammation and immunity, and its disruption may impair tumor response to immunotherapy and chemotherapy. Here, the rationale and design of the multi-center, single-arm ABC-12 trial (ISRCTN11210442) is described, which investigates the role of the microbiome in patients with advanced BTC in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine. The primary objective is to determine the difference in baseline alpha diversity between 'responders' (partial or complete response) and 'non-responders' at 18 weeks (RECIST 1.1) in patients treated with cisplatin/gemcitabine/durvalumab. Secondary objectives include investigating the association between microbiome parameters and objective response rate, tumor control (partial, complete response, and stable disease), progression-free and OS, and investigating the interaction between treatment effect and microbiome parameters on clinical outcomes.
Description
Date
2025
Publisher
Collections
Keywords
Type
Article
Citation
Vrana E, Timmins H, Osborne A, Cox R, Wasan H, Ma YT, et al. ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine. Future oncology (London, England). 2025 Sep;21(21):2713-21. PubMed PMID: 40728861. Pubmed Central PMCID: PMC12407636 plus gemcitabine was the standard chemotherapy regimen for patients with BTC where surgery was not possible. Durvalumab is an immunotherapy which works by assisting the immune system to recognize and attack cancer cells. The addition of durvalumab to cisplatin and gemcitabine has shown a survival benefit.Thousands of bacteria live in the human digestive system, which are called the microbiota. Each person has an individual community of microorganisms, and the microbiome is a collection of genomes (genetic material) from all the microorganisms in the environment, and this varies greatly from one person to the other. This is responsible for the breakdown of food, changing food into energy for the body, and protecting against infections. It also helps in developing the immune system. Research shows that its disruption can cause disease, including cancer, and can affect response to chemotherapy and immunotherapy. The aim of this trial is to assess whether the number and types of bacteria that live naturally in saliva and the bowel impact the response to the combination of immunotherapy with cisplatin and gemcitabine in patients with biliary tract cancer, where cure is not possible. Epub 2025/07/29. eng.